Table 1.

Patient cohorts and sample sizes involved in the different study phases

Sample size
n = 1,357 (%)Age (SD)a
Study arm I: Discovery and validation of biomarker panel for primary UBC72166 (±13)
Overall primary UBC patients509 (71%)68 (±12)
Overall urologic controls212 (29%)63 (±15)
Discovery phase45166 (±13)
 Primary UBC patients341 (76%)67 (±12)
 Urologic controls110 (24%)60 (±16)
Validation phase27068 (±12)
 Primary UBC patients168 (62%)69 (±11)
 Urologic controls102 (38%)65 (±14)
Study arm II: Discovery and validation of biomarker panel for recurrent UBC63668 (±12)
Overall UBC patients with recurrent disease164 (26%)70± (11)
Overall UBC patients without recurrent disease (“recurrent controls”)472 (74%)68± (12)
Discovery phase42569 (±12)
 UBC patients with recurrent disease109 (26%)71± (10)
 UBC patients without recurrent disease316 (74%)68± (12)
Validation phase21168 (±13)
 UBC patients with recurrent disease55 (26%)69± (13)
 UBC patients without recurrent disease156 (74%)68± (13)
  • Abbreviation: UBC, urothelial bladder cancer.

  • aMean value.